Worth reading
34Immaterial
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
The acquisitionCounterparty (target company)Ultradent Products, inc.
Disclosing companyMitsui Chemicals,Inc.
Execution Date / Effective Date14 August 2026 (local time; completed)
Target company
Location United States
Impact on Business Performance
Currently under review. If any matter requiring disclosure arises, it will be disclosed promptly.
Procedures and assumptions
Conditions Precedent to ExecutionRequired regulatory approvals and filings under competition and investment regulation laws
Management structure after acquisitionThe global headquarters functions of the oral care business will be transferred from Japan to a U.S. holding company.
| Item | Details |
|---|---|
| Transaction name | The acquisition |
| Counterparty name | Ultradent Products, inc. |
| Name of the Subject Company | Ultradent Products, inc. |
| Location of the Subject Company | United States |
| Impact on Business Performance | Currently under review. If any matter requiring disclosure arises, it will be disclosed promptly. |
| Execution Date / Effective Date | 14 August 2026 (local time; completed) |
| Conditions Precedent to Execution | Required regulatory approvals and filings under competition and investment regulation laws |
| Management structure after acquisition | The global headquarters functions of the oral care business will be transferred from Japan to a U.S. holding company. |
Items this document does not state (24)
Business Description of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The required regulatory approvals and filings under competition and investment regulation laws were completed earlier than expected. Following the acquisition, the company plans to transfer the global headquarters functions of its oral care business from Japan to a U.S. holding company, with the aim of maximizing integration benefits across the group and becoming a leading company in the oral care field.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.